Archives
Influence and management of conflicts of interest in randomized clinical trials: qualitative interview study
2 Nov, 2020 | 02:22h | UTC
Commentary on Twitter
In a great qualitative interview study @bmj_latest @LasseOstengaard, @AndreasLundh2 & colleagues show some staggering trialist comments on how trial sponsors tried to influence the clinical trials with manipulation, spin and selective reporting https://t.co/KN25JeYErU pic.twitter.com/2leb0OQmCG
— Lars Villads Bennedsen, MD PhD GP (@LarsJorgensenMD) October 30, 2020
Expert analysis: Efficacy and safety of colchicine in patients with chronic stable coronary disease
2 Nov, 2020 | 02:18h | UTC
Randomized trial: Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions
2 Nov, 2020 | 02:17h | UTC
Report: COVID-19 infection fatality ratio estimates from seroprevalence
30 Oct, 2020 | 01:16h | UTCFull report: COVID-19 Infection Fatality Ratio: Estimates from Seroprevalence
Commentary on Twitter
UPDATE #COVID19 Infection Fatality Ratio (IFR):
➡️1.15% IFR (high income countries)
➡️0.23% IFR (low income countries)
➡️0.1% IFR (under 40 year olds)
➡️5.6% IFR (over 80 year olds)
➡️Risk of COVID19 death doubles every eight years of age👇Report 34 https://t.co/171hx5LMvp pic.twitter.com/M1rmq673Rf
— MRC Centre for Global Infectious Disease Analysis (@MRC_Outbreak) October 29, 2020
CDC Report: 1 infected camper likely led to 115 coronavirus cases at an overnight camp
30 Oct, 2020 | 01:15h | UTCOriginal report: COVID-19 Outbreak at an Overnight Summer School Retreat ― Wisconsin, July–August 2020 – CDC Morbidity and Mortality Weekly Report
Commentary on Twitter
When 1 high school student who tested covid negative 1 week prior to a retreat led to 116 cases (76% of the students and staff)https://t.co/vjKImeE4vg @CDCgov
— Eric Topol (@EricTopol) October 29, 2020
Case study: Urinary magnesium in the evaluation of hypomagnesemia
2 Nov, 2020 | 02:19h | UTCUrinary Magnesium in the Evaluation of Hypomagnesemia – JAMA (free for a limited period)
Perspective: Will SARS-CoV-2 become endemic?
30 Oct, 2020 | 01:12h | UTCWill SARS-CoV-2 become endemic? – Science
It may be time to reset expectations on when we’ll get a Covid-19 vaccine
30 Oct, 2020 | 01:10h | UTCIt may be time to reset expectations on when we’ll get a Covid-19 vaccine – STAT
The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug
30 Oct, 2020 | 01:14h | UTCThe ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug – Science
Commentaries on Twitter
Remdesivir, despite failing in Solidarity trial, received FDA approval without input from outside advisory group. EU cut pricing deal with Gilead without knowing Solidarity data. @kakape and I explain in "The ‘very, very bad look’ of remdesivir" https://t.co/yTKq2A1WQT pic.twitter.com/NhBLum09VG
— Jon Cohen (@sciencecohen) October 28, 2020
Uncovering a scandal about Gilead and Remdesivir
Deep reporting by @sciencecohen and @kakape @ScienceMagazine
The company knew the #SOLIDARITY trial data well before it its preprint. And so did the FDA before giving a full approval, w/o external review https://t.co/4REMEwTvc5— Eric Topol (@EricTopol) October 28, 2020
Perspective: Why schools probably aren’t COVID hotspots
30 Oct, 2020 | 01:11h | UTCWhy schools probably aren’t COVID hotspots – Nature
Opinion: For now, it’s unethical to use human challenge studies for SARS-CoV-2 vaccine development
30 Oct, 2020 | 01:09h | UTC
A room, a bar and a classroom: how the coronavirus is spread through the air
30 Oct, 2020 | 01:08h | UTCA room, a bar and a classroom: how the coronavirus is spread through the air – El Pais
Commentary on Twitter (thread – click for more)
https://twitter.com/ASPphysician/status/1321798685991186434
Videos in clinical medicine: Percutaneous Tracheostomy
30 Oct, 2020 | 01:05h | UTCPercutaneous Tracheostomy – New England Journal of Medicine
AHA Scientific Statement: Prevention of complications in the cardiac intensive care unit
30 Oct, 2020 | 01:06h | UTCCommentary: New strategies suggested for critical heart care in the ICU – American Heart Association
Non-surgical management of knee osteoarthritis: Comparison of ESCEO and OARSI 2019 guidelines
30 Oct, 2020 | 01:02h | UTCCommentary: Knee OA guidance for clinicians simplified and streamlined – University of Oxford
Study provides new estimates of breast cancer risks associated with different hormone replacement therapy preparations
30 Oct, 2020 | 01:04h | UTCCommentaries: Study provides new estimates of breast cancer risks associated with HRT – University of Oxford AND New estimates of breast cancer risks associated with HRT – The BMJ AND HRT: Breast Ca Risk Tied to Hormone Type, Duration of Tx – Physician’s Weekly
KDIGO Controversies Conference on onco-nephrology
30 Oct, 2020 | 01:03h | UTC
Commentary on Twitter
.@goKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer ca. 2020 from @Kidney_Int #Nephpearls#Onconephrology 🦀
👉🏼 https://t.co/u6ANtXdKfy pic.twitter.com/4xJ0gGohoE— Edgar V. Lerma 🇵🇭 (@edgarvlermamd) October 28, 2020
Randomized phase 2 trial: SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19
29 Oct, 2020 | 09:16h | UTCAudio Interview: A New Monoclonal Antibody for Covid-19 – New England Journal of Medicine
Commentaries on Twitter
BLAZE-1🔥 – outpatient trial of LY-Cov555, mAb recently dropped from ACTIV-3 inpatient trial
Only 1 of the 3 mAb dosages (middle one 🤷♂️) ⬇️ VL by d11
mAb assoc with modest ⬇️ in healthcare visits (1.6% vs 6.3% for placebo)
😑 Far from a game changerhttps://t.co/zZMGlodaaF pic.twitter.com/ofs1UgN1ZA
— Ilan Schwartz is on🦋 (@GermHunterMD) October 28, 2020
Phase 2 Lilly #SARSCoV2 monoclonal antibody outpatient trial just published @NEJM
The lack of a dose response for viral load reduction +modest effects on symptoms do not make this look like a potent intervention https://t.co/oyRG8fUNHf pic.twitter.com/uobuCIznmD— Eric Topol (@EricTopol) October 28, 2020
Humoral immune response to SARS-CoV-2 in Iceland
29 Oct, 2020 | 09:18h | UTCHumoral Immune Response to SARS-CoV-2 in Iceland – New England Journal of Medicine
Editorial: The Power of Antibody-Based Surveillance – New England Journal of Medicine
Video: Coronavirus update with Anthony Fauci – October 28, 2020
29 Oct, 2020 | 09:11h | UTCCoronavirus Update With Anthony Fauci – October 28, 2020 – JAMA
Clinical practice: Mild or moderate Covid-19
29 Oct, 2020 | 09:12h | UTCMild or Moderate Covid-19 – New England Journal of Medicine
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2
29 Oct, 2020 | 09:09h | UTC
Commentary on Twitter
NEW—What defines an efficacious #COVID19 vaccine? Experts @JennerInstitute@OxfordVacGroup @OxPrimaryCare & @OxfordBRC outline key challenges for assessing clinical efficacy of vaccines against SARS-CoV-2 @TheLancetInfDis https://t.co/QsLnLdUiYE pic.twitter.com/skpb0rfSdF
— The Lancet (@TheLancet) October 28, 2020
Clinical Decisions: Elective surgery during the Covid-19 pandemic
29 Oct, 2020 | 09:14h | UTCElective Surgery during the Covid-19 Pandemic – New England Journal of Medicine
Randomized trial: Validation of an enhanced recovery after surgery protocol in gynecologic surgery
29 Oct, 2020 | 09:07h | UTCRelated Systematic Review: Multicomponent hospital-led interventions to reduce hospital stay for older adults following elective surgery: a systematic review – Health Services and Delivery Research AND Summary: People leave hospital after surgery sooner if hospitals follow ‘enhanced recovery protocols’ – NIHR
See also: Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines (free articles)
Commentary on Twitter
Validation of an enhanced recovery after surgery protocol in gynecologic surgery: an Italian randomized study- https://t.co/VRZ1LKzEvJ pic.twitter.com/2G1InEcIEZ
— AJOG (@AJOG_thegray) October 27, 2020
Report: Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
29 Oct, 2020 | 09:08h | UTCRobust neutralizing antibodies to SARS-CoV-2 infection persist for months – Science
Commentary on Twitter
Just published @ScienceMagazine. >30,000 people w/mild to moderate #COVID19 have excellent IgG antibody titers for several months. No disappearing act. Important👍👍https://t.co/4kCZY8qcmo @MountSinaiNYC @FatimaAmanat @DrDavidReich @florian_krammer @IcahnMountSinai et al
, pic.twitter.com/B3LJ6JaBDa— Eric Topol (@EricTopol) October 28, 2020